Blueprint Medicines (BPMC)

P/S ratio as of March 2025 (TTM): 11.7

According to Blueprint Medicines 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 20.0. At the end of 2024 the company had a P/S ratio of 11.2.

P/S ratio history for Blueprint Medicines from 2015 to 2024

PS ratio at the end of each year

Year	P/S ratio	Change
2024	11.2	-50.36%
2023	22.5	75.02%
2022	12.8	-63.29%
2021	35.0	344.43%
2020	7.87	-86.73%
2019	59.3	11.29%
2018	53.3	-65.14%
2017	153	357.88%
2016	33.4	-46.58%
2015	62.5

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Isoray ISR	11.9	1.65%	🇺🇸 USA
OPKO Health OPK	1.62	-86.16%	🇺🇸 USA
Pacific Biosciences PACB	2.40	-79.58%	🇺🇸 USA
Acceleron Pharma XLRN	N/A	N/A	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Blueprint Medicines (BPMC)

P/S ratio as of March 2025 (TTM): 11.7